摘要
目的:研究知柏地黄合五苓汤联合TP化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及对化疗所致肾损伤的防治作用。方法:选取2020年1月—2022年1月郑州市第三人民医院住院的116例晚期NSCLC患者作为研究对象,以随机数表法分为对照组和联合组,每组各58例。对照组应用TP化疗方案,联合组在对照组基础上应用知柏地黄合五苓汤。比较两组患者的临床、肾功能、不良反应及生存质量。结果:联合组的疾病控制率(DCR)高于对照组,差异有统计学意义(χ^(2)=4.130,P<0.05);治疗后,联合组血清血肌酐(Scr)、尿素氮(BUN)及24 h尿蛋白定量(24 h UPR)均低于对照组,差异有统计学意义(t=9.327、3.703、2.357,P<0.05);与对照组比较,联合组毒副反应总发生率更低,差异有统计学意义(χ^(2)=0.967、0.689、0.120、4.674,P<0.05);治疗后,联合组治疗后Karnofsky (KPS)评分高于对照组,差异有统计学意义(t=5.849,P<0.001)。结论:在晚期NSCLC患者中应用知柏地黄合五苓汤联合TP化疗较单用TP化疗具有更好的疗效,安全性更佳,能有效改善患者生存质量。
Objective:To study the curative effect of Zhibaidihuang and Wuling decoction combined with TP chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and the prevention and treatment of renal injury.Methods:A total of 116 patients with advanced NSCLC who were hospitalized from January 2020 to January 2022 were selected,and divided into control group and combined group by random number table,with 58 cases in each group.Control group applied TP chemotherapy regimen,and combined group applied Zhibaidihuang and Wuling decoction based on the control group.The clinical and renal functions,adverse effects and survival quality of the 2 groups were compared.Results:The disease control rate(DCR)of the combined group was higher than that of the control group,and the difference was statistically significant(χ^(2)=4.130,P<0.05).After treatment,serum creatinine(Scr),urea nitrogen(BUN)and 24 h urinary protein(24 h UPR)in the combined group were lower than those in the control group,and the differences were statistically significant(t=9.327,3.703,2.357;P<0.05).Compated with control group,total toxic and side effect with statistically significant difference(χ^(2)=0.967,0.689,0.120,4.674;P<0.05).After treatment,the Karnofsky(KPS)score of the combined group was higher than that of the control group,and the difference was statistically significant(t=5.849,P<0.001).Conclusion:The application of Zhiping Dihuanghe Wuling Decoction combined with TP chemotherapy in patients with advanced NSCLC has better efficacy and better safety than TP chemotherapy alone,and can effectively improve the quality of patient survival.
作者
马丽
张培利
胡俊俊
Ma Li;Zhang Peili;Hu Junjun(Department of Pharmacy,The Third People’s Hospital of Zhengzhou,Zhengzhou,Henan,450000,China)
出处
《黑龙江医学》
2024年第8期905-907,911,共4页
Heilongjiang Medical Journal
关键词
非小细胞肺癌
知柏地黄丸
五苓汤
肾损伤
Non small cell lung cancer
Zhibaidihuang Pill
Wuling Decoction
Kidney injury
